Traditionally, treatment for chronic conditions addressed symptoms or was disease modifying and required lifelong periodic administration and recurring costs. This research extends a previous study by analyzing member retention for adult patients with certain rare diseases.
This JMCP study compares pay-for-success and pay-for-failure models to identify the short- and long-term incentives for each that manufacturers and payers should consider when developing value-based contracts. More research is needed on the effect of different types of value-based contract schemes on cost and clinical outcomes.
This JMCP study compares pay-for-success and pay-for-failure models to identify the short- and long-term incentives for each that manufacturer and payer should when developing value-based contracts. More research is needed on the effect of different types of value-based contract schemes on cost and clinical outcome.
Although interest in value assessment frameworks is relatively widespread among payers, significant challenges to operationalizing them exist within the U.S. healthcare system. Those challenges--which include existing policies and a lack of standardized definitions--restrict the ability to make favorable contracts.
Although interest in value assessment frameworks is relatively widespread among payers, significant challenges to operationalizing them exist within the U.S. healthcare system. Those challenges--which include existing policies and a lack of standardized definitions--restrict the ability to make favorable contracts.
Major reasons for the slow uptake of outcomes-based risk-sharing agreements in the U.S. are regulatory issues, operational requirements, and deficits in information sharing, according to a literature review published in JMCP.
Major reasons for the slow uptake of outcomes-based risk-sharing agreements in the U.S. are regulatory issues, operational requirements, and deficits in information sharing, according to a literature review published in JMCP.